Nevertheless, the development of SIRT6 inhibitors has also been pursued as these compounds could find application in some cancer types, in which SIRT6 seems to have pro-oncogenic effects (i.e., squamous cell carcinomas, pancreatic cancer, acute myeloid leukemia, and multiple myeloma), such as increasing cell migration, tumor DNA repair, and secretion of pro-angiogenic factors [5, 13, 26, 27]. The gene discussed is SIRT6; the disease is plasma cell myeloma.